Amgen secures FDA Priority Review for tarlatamab to treat SCLC
Tarlatamab is an investigational, delta-like ligand 3 (DLL3) targeting Bispecific T-cell Engager (BiTE) therapy intended for the treatment…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
14 Dec 23
Tarlatamab is an investigational, delta-like ligand 3 (DLL3) targeting Bispecific T-cell Engager (BiTE) therapy intended for the treatment…
14 Dec 23
The system includes a hollow-fibre module and draw solution for organic solvents to optimise the manufacturing processes in…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
14 Dec 23
The fourth generation BDTX-1535 is an oral, brain-penetrant, covalent EGFR inhibitor, which is currently in Phase 1 clinical…
14 Dec 23
Vertex Pharmaceuticals to obtain a non-exclusive license for Cas9 for CASGEVY
13 Dec 23
The acquisition will strengthen AstraZeneca’s vaccines and immune therapies pipeline with Icosavax’s lead investigational vaccine candidate IVX-A12, a…
13 Dec 23
The collaboration is aimed at developing new gene therapies for undisclosed CNS diseases by leveraging JCR Pharmaceuticals' proprietary…
13 Dec 23
The trial assessed Darzalex SC formulation-based quadruplet induction, consolidation regimen and doublet maintenance regimen in patients with transplant-eligible…
13 Dec 23
Funding comes on the heels of positive top-line clinical results and will advance clinical development of its lead…
12 Dec 23
The merger will combine Sigma’s distribution infrastructure and CWG’s retailing know-how to create a full-service wholesaler, distributor, and…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
12 Dec 23
The authorisation of the indication also converts previous conditional approval for Jemperli to full approval as a monotherapy…